Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 May 2020 12:04 PM
RNS
Result of General Meeting
19 May 2020 02:00 PM
RNS
Group Projects Summary & Board Expansion Plans
07 May 2020 02:05 PM
RNS
Second Price Monitoring Extn
07 May 2020 02:01 PM
RNS
Price Monitoring Extension
07 May 2020 07:00 AM
RNS
Appointment of Director
06 May 2020 04:23 PM
RNS
Posting of Circular and Notice of General Meeting
06 May 2020 09:05 AM
RNS
Holding(s) in Company
04 May 2020 03:00 PM
RNS
Broker Option - Fully Subscribed
04 May 2020 08:27 AM
RNS
Holding(s) in Company
04 May 2020 08:24 AM
RNS
Holding(s) in Company
04 May 2020 07:00 AM
RNS
Conditional Fundraise of £1.2 million
01 May 2020 01:34 PM
RNS
Share Price Movement
01 May 2020 09:21 AM
RNS
Holding(s) in Company
01 May 2020 08:16 AM
RNS
Material Transfer Agreement
01 May 2020 07:00 AM
RNS
Proposed appointment of Director
30 Apr 2020 08:00 AM
RNS
Holding(s) in Company
30 Apr 2020 07:00 AM
RNS
Change of Management Team
29 Apr 2020 05:42 PM
RNS
Statement re social media reports
24 Apr 2020 07:00 AM
RNS
Holding(s) in Company
23 Apr 2020 11:04 AM
RNS
Holding(s) in Company
16 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
16 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
14 Apr 2020 12:41 PM
RNS
Result of General Meeting & Directorate Change
14 Apr 2020 10:08 AM
RNS
Change of Director
09 Apr 2020 02:39 PM
RNS
Change of Arrangements for General Meeting
01 Apr 2020 11:59 AM
RNS
Result of General Meeting
01 Apr 2020 07:00 AM
RNS
Conditional Placing
30 Mar 2020 07:00 AM
RNS
Update
25 Mar 2020 09:44 AM
RNS
General Meeting - Adjournment
16 Mar 2020 07:00 AM
RNS
Posting of Circular & Notice of General Meeting
10 Mar 2020 07:00 AM
RNS
Posting of Circular & Notice of General Meeting
04 Mar 2020 03:28 PM
RNS
Shareholder Requisition Notice
17 Feb 2020 02:05 PM
RNS
Second Price Monitoring Extn
17 Feb 2020 02:00 PM
RNS
Price Monitoring Extension
17 Feb 2020 12:07 PM
RNS
Result of General Meeting & working capital update
12 Feb 2020 07:00 AM
RNS
Change of Venue for General Meeting-17 Feb 2020
30 Jan 2020 02:00 PM
RNS
Posting of Circular & Notice of General Meeting
14 Jan 2020 07:00 AM
RNS
Update - ValiSeek
06 Jan 2020 07:00 AM
RNS
Placing, Issue of Warrant & Appointment of Broker
16 Dec 2019 09:05 AM
RNS
Second Price Monitoring Extn
16 Dec 2019 09:00 AM
RNS
Price Monitoring Extension
16 Dec 2019 07:00 AM
RNS
VAL201 Update
28 Nov 2019 07:00 AM
RNS
US Patent Grant re VAL201 & Metastatic Cancer
13 Nov 2019 11:33 AM
RNS
Holding(s) in Company
13 Nov 2019 07:00 AM
RNS
Appointment of Joint Broker
11 Nov 2019 03:30 PM
RNS
Holding(s) in Company
21 Oct 2019 11:47 AM
RNS
Passing of Non-Executive Chairman
14 Oct 2019 01:23 PM
RNS
Placing & Issue of Equity
09 Oct 2019 04:35 PM
RNS
Price Monitoring Extension
26 Sep 2019 07:00 AM
RNS
Half-year Report

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings